Cargando…

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases

Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi-organ involvement. This entity has displaced viral hepatitis as the main cause of severe forms of hepatic diseases,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallego-Durán, Rocío, Montero-Vallejo, Rocío, Maya-Miles, Douglas, Lucena, Ana, Martin, Franz, Ampuero, Javier, Romero-Gómez, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652219/ https://www.ncbi.nlm.nih.gov/pubmed/34899679 http://dx.doi.org/10.3389/fimmu.2021.667354

Ejemplares similares

Contribution of Liver and Pancreatic Islet Crosstalk to β-Cell Function/Dysfunction in the Presence of Fatty Liver
por: López-Bermudo, Lucía, et al.
Publicado: (2022)

Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD
por: Ampuero, Javier, et al.
Publicado: (2022)

Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool
por: Marañón, Patricia, et al.
Publicado: (2022)

Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation
por: Gallego-Durán, Rocío, et al.
Publicado: (2022)

Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients
por: Gil-Gómez, Antonio, et al.
Publicado: (2022)

Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study
por: Muñoz-Hernández, Rocío, et al.
Publicado: (2020)

Wilson's disease: Revisiting an old friend
por: Lucena-Valera, Ana, et al.
Publicado: (2021)

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
por: Gallego-Durán, Rocío, et al.
Publicado: (2016)

Impact of COVID-19 on liver disease: From the experimental to the clinic perspective
por: Gato, Sheila, et al.
Publicado: (2021)

Extracellular Vesicles as Biomarkers in Liver Disease
por: Muñoz-Hernández, Rocío, et al.
Publicado: (2022)

Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies
por: Rojas, Ángela, et al.
Publicado: (2022)

Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis
por: Marañón, Patricia, et al.
Publicado: (2023)

Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD)
por: Del Campo, José A, et al.
Publicado: (2018)

Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients
por: Gil-Gómez, Antonio, et al.
Publicado: (2021)

Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease
por: Duan, Yamei, et al.
Publicado: (2022)

Macrophages and the development and progression of non-alcoholic fatty liver disease
por: Alabdulaali, Bader, et al.
Publicado: (2023)

The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity
por: Van Herck, Mikhaïl A., et al.
Publicado: (2019)

General Overview About the Current Management of Nonalcoholic Fatty Liver Disease
por: Ampuero, Javier
Publicado: (2022)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
por: Valenzuela-Vallejo, Laura, et al.
Publicado: (2023)

Retained NK Cell Phenotype and Functionality in Non-alcoholic Fatty Liver Disease
por: Stiglund, Natalie, et al.
Publicado: (2019)

Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack
por: Oates, Jarren R., et al.
Publicado: (2019)

Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease
por: Martínez-Chantar, María Luz, et al.
Publicado: (2021)

The immune response as a therapeutic target in non-alcoholic fatty liver disease
por: Ortiz-López, Nicolás, et al.
Publicado: (2022)

A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy
por: Guo, Feifei, et al.
Publicado: (2021)

Chemokines in Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis
por: Pan, Xiongfeng, et al.
Publicado: (2020)

The Absence of STING Ameliorates Non-Alcoholic Fatty Liver Disease and Reforms Gut Bacterial Community
por: Zhang, Qiang, et al.
Publicado: (2022)

Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease
por: Lambrecht, Joeri, et al.
Publicado: (2021)

Nutrition could prevent or promote non-alcoholic fatty liver disease: an opportunity for intervention
por: Romero-Gómez, Manuel, et al.
Publicado: (2023)

Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy
por: del Campo, José A., et al.
Publicado: (2018)

Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools
por: Meli, Rosaria, et al.
Publicado: (2014)

Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns
por: Zeng, Fanhong, et al.
Publicado: (2021)

Glycyrrhetinic acid regulates impaired macrophage autophagic flux in the treatment of non-alcoholic fatty liver disease
por: Fan, Yadong, et al.
Publicado: (2022)

Thermoneutral housing shapes hepatic inflammation and damage in mouse models of non-alcoholic fatty liver disease
por: Oates, Jarren R., et al.
Publicado: (2023)

Emerging pharmacological treatment options for MAFLD
por: Rojas, Ángela, et al.
Publicado: (2022)

Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease
por: Zhou, Liangliang, et al.
Publicado: (2022)

SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease
por: Novo, Erica, et al.
Publicado: (2022)

Helminth infection and helminth-derived products: A novel therapeutic option for non-alcoholic fatty liver disease
por: Liu, Xi, et al.
Publicado: (2022)

The association between non-alcoholic fatty liver disease and atopic dermatitis: a population-based cohort study
por: Gau, Shuo-Yan, et al.
Publicado: (2023)

Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do
por: Sanchez-Torrijos, Yolanda, et al.
Publicado: (2017)

HIV, Cancer, and the Microbiota: Common Pathways Influencing Different Diseases
por: Herrera, Sabina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t8atrbn8mgedp7n45tslkoka0q